Suzhou Genhouse Bio Co., Ltd.
Clinical trials sponsored by Suzhou Genhouse Bio Co., Ltd., explained in plain language.
-
New Two-Pronged attack on advanced cancers begins human testing
Disease control Not yet recruitingThis early-stage study is testing a new combination of two oral drugs, GH55 and GH21, for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if blocking two specific cancer growth pathways at once is safe and can help control…
Phase: PHASE1, PHASE2 • Sponsor: Suzhou Genhouse Bio Co., Ltd. • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC
-
New drug duo targets Tough-to-Treat KRAS cancers
Disease control Not yet recruitingThis study is testing whether combining two experimental drugs, GH21 and D-1553, can help control advanced cancers that have a specific genetic change called KRAS G12C. It is for adults with lung cancer or other solid tumors who have already tried standard treatments and a previo…
Phase: PHASE2 • Sponsor: Suzhou Genhouse Bio Co., Ltd. • Aim: Disease control
Last updated Mar 16, 2026 15:25 UTC